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Guidelines for Laboratory Test Result Reporting
of Human Immunodeficiency Virus Type 1
Ribonucleic Acid Determination
Recommendations from a CDC Working Group
Summary
Monitoring human immunodeficiency virus type 1 (HIV-1) ribonucleic acid
levels (also known as HIV viral load ) has become the standard of care for
monitoring response to therapy in HIV-infected patients. In 1999, CDC published
updated surveillance case definitions for HIV infection and acquired
immunodeficiency syndrome (AIDS) reporting, including positive results of HIV-1
viral detection tests (CDC. Guidelines for national human immunodeficiency virus
case surveillance, including monitoring for human immunodeficiency virus
infection and acquired immunodeficiency syndrome. MMWR 1999;48[No. RR-
13]:1–28). Since 1996, an increased number of public and private laboratories
have begun performing viral load tests. Results obtained with available test
methods are variable, and laboratories present these results in different ways,
indicating that guidelines to promote standard practice in reporting of test results
are warranted. This report provides guidelines for standardized reporting of viral
load test results by licensed laboratories to health-care providers and facilities for
public health case reporting of HIV infection and AIDS. Recommended standards
were developed through data review, input involving a working group of
physicians and laboratorians experienced in viral load testing, and an assessment
of laboratory practices. These guidelines were discussed, refined, and endorsed
at the annual Human Retrovirus and Hepatitis C Laboratory Testing Conference,
held March 6–9, 2000, in Charlotte, North Carolina, with participation of
representatives from public health, hospital, independent, and blood-collection–
facility laboratories. Adoption of these guidelines by all public and private
laboratories that perform HIV viral load testing will improve the quality and
usefulness of viral load test results for the physician ordering the test and for
reporting to public health departments.
INTRODUCTION
Using highly active antiretroviral therapy (HAART) and monitoring therapy response
by using viral load testing have contributed to clinical management of persons infected
with human immunodeficiency virus (HIV) (1–26 ). Measurements of viral load and CD4+
lymphocytes are used to determine when antiretroviral therapy should be initiated and
to monitor treatment efficacy (27–35 ). Since 1996, an increasing number of laboratories
have been performing viral load tests. In 1999, CDC’s Model Performance Evaluation
Program (MPEP) conducted a laboratory questionnaire survey, which determined that
51% of the laboratories performing viral load tests had begun doing so in the previous 2
years and 37% had begun in the previous 3–4 years. No test reporting standardization
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exists; specifically, standard units of measurement of test method have not been estab-
lished. Laboratory viral load test reports should be accurate and adequate for patient
treatment and public health monitoring of the HIV and acquired immunodeficiency syn-
drome (AIDS) epidemic. To assure test reporting comparability among laboratories, stan-
dard methods are needed; moreover, standardized results are needed for early detection
of infection, early access to patient care, and early detection of treatment failure.
On January 1, 2000, the CDC HIV-infection surveillance case definition was expanded
to include viral load test results (34 ). HIV ribonucleic acid (RNA) viral load reporting is
critical in monitoring patients’ progression toward AIDS and response to HAART. For
public health purposes, viral load reporting is key to expanding surveillance of HIV-
infection reporting and improving monitoring of the epidemic. Surveillance programs for
HIV/AIDS in the United States, specifically states initiating HIV-infection reporting, will
rely on laboratory viral load test reporting to identify prevalent HIV infections among
persons who are in care and receiving routine viral load monitoring. Test-reporting stan-
dardization will facilitate progress toward electronic laboratory reporting, which is key to
increasing efficiency among disease surveillance programs.
On November 30, 1999, CDC convened a working group of physicians and
laboratorians experienced in HIV testing and representing the Food and Drug Adminis-
tration (FDA), the Association of Public Health Laboratories (APHL), and the College of
American Pathologists to address standardization of laboratory reporting of HIV type 1
(HIV-1) viral load testing results. The working group reviewed information regarding
variations in test reporting and interkit variation of test results. At the conclusion of this
meeting, the working group developed recommendations, which were discussed, re-
fined, and endorsed at the annual Human Retrovirus and Hepatitis C Laboratory Testing
Conference, held March 6–9, 2000, in Charlotte, North Carolina, and sponsored by APHL,
with participation of representatives from public health, hospital, independent, and blood-
collection–facility laboratories.*
This report provides recommendations for standardizing viral load test reports from
licensed laboratories to health-care providers and facilities and reporting HIV infection
and AIDS cases for public health surveillance. These guidelines do not include a) recom-
mendations for using viral load tests for clinical management, which are reported else-
where (35,36 ); b) laboratory safety standards; c) specimen collection, transport, integrity,
storage, processing, and analysis; d) data analysis, storage, and transmission; or quality
assurance, which is also reported elsewhere (37 ).
BACKGROUND
Available Viral Load Tests
Three commercially available test kits are routinely used for detecting and quantitat-
ing HIV RNA in plasma, including a) the Roche® Amplicor HIV-1 Monitor™ (Roche Diag-
*The conference report can be ordered from APHL at
Association of Public Health Laboratories
2025 M Street, N.W., No. 550
Washington, DC 20036-3320
Phone: 202-822-5227
Fax: 202-887-5098
Internet: <http://www.aphl.org> (accessed July 19, 2001)
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nostic Systems, Inc.); b) the Bayer Corporation, Diagnostics Division, assay (designated
as the Bayer VERSANT® HIV-1 RNA 3.0 Assay [branched chain deoxyribonucleic acid or
bDNA], but formerly designated as the Bayer HIV-1 RNA 3.0 Quantitative Assay [bDNA])
and the Bayer Quantiplex™ HIV-1 RNA [bDNA]); and c) the Organon Teknika NucliSens®
HIV-1 QT. Of these, the Roche Amplicor HIV-1 Monitor is the only FDA-approved test kit.
The methods these kits employ and their range of detection sensitivities are provided in
this report (Table 1).
The Roche assay is based on a target amplification system and uses reverse
transcriptase-polymerase chain reaction (RT-PCR) technology. This assay is available in
two versions, 1.0 and 1.5. Version 1.0 is the standard assay and the only FDA-approved
assay. The manufacturer has developed a method to increase the sensitivity of the
standard assay, and this ultrasensitive method can be used only with version 1.0. Version
1.0 was developed for quantitation of HIV-1 subtype B, the predominant subtype in North
America, whereas version 1.5 has been designed to improve equivalent quantitation of
non-B subtypes. The Bayer assay, versions 2.0 and 3.0, are based on signal amplification
that uses bDNA technology. The Organon Teknika assay is a transcription-based isother-
mal target amplification method employing nucleic acid sequence-based amplification
(NASBA) technology. The NucliSens HIV-1 QT is the present version of the Organon
Teknika assay.*
TABLE 1. Reportable range of the Roche® Amplicor HIV-1 Monitor™, Bayer HIV-1 RNA
(ribonucleic acid) assay (branched deoxyribonucleic acid), and Organon Teknika HIV-1
(human immunodeficiency virus type 1) QT assay used for HIV-1 viral load testing
Manufacturer Amplification method Reportable range
Roche Reverse transcriptase-polymerase Standard assay: 400–750,000
chain reaction/target (RT-PCR) copies/mL
Ultrasensitive method:
50–75,000 copies/mL
Bayer Branched chain deoxyribonucleic Version 2.0: 500–1,600,000
acid/signal (bDNA) copies/mL
Version 3.0: 50–500,000
copies/mL
Organon Teknika Nucleic acid sequence-based Nucleic acid sequence-based
amplification/target (NASBA) amplification: 400–15,000,000
copies/mL
NucliSens:® 40–10,000,000
copies/mL
*Certain enzyme immunoassay (EIA or enzyme-linked immunosorbent assay [ELISA])
screening and Western blot confirmatory tests used in the United States reliably detect HIV-
1 infection but not HIV-2 infection. HIV infections acquired in Africa, specifically West Africa,
might be HIV-2 infection and escape detection if assays optimized for HIV-1 are used. Health-
care providers who perform HIV tests on patients who might have been exposed in Africa
(e.g., returning visitors or newly arriving immigrants and refugees) should use EIAs that are
licensed for detection of both HIV-1 and HIV-2. Additionally, the majority of commercially
available tests that are used to detect HIV RNA viral load are effective for HIV-1 subtype B but
not other HIV-1 subtypes (e.g., A, C, D, or E). No FDA-approved tests for quantification of
non-B HIV subtypes exist. HIV infections acquired outside the United States might be HIV-
1 non-B subtypes. Therefore, when testing patients for viral load who might have been
exposed in Africa or other overseas locations, assays that are effective for multiple HIV-1
subtypes (HIV-2 RNA viral load tests are not commercially available) should be used.
4 MMWR November 16, 2001
Sensitivities of HIV viral load detection vary by test kit type. The Roche standard
assay kit has a reportable range of 400–750,000 copies/mL of plasma, whereas the
ultrasensitive method has a range of 50–75,000 copies/mL (38 ). Bayer assay versions
2.0 and 3.0 have a detection range of 500–1,600,000 and 50–500,000 copies/mL, respec-
tively (39 ). The Organon Teknika’s initial NASBA HIV-1 RNA QT detection range was 400–
15,000,000 copies/mL, but the NucliSens HIV-1 QT has a detection range of 40–10,000,000
copies/mL (40 ).
Laboratory Practices for HIV Viral Load Testing
In 1997, CDC’s MPEP implemented an ongoing performance evaluation of laborato-
ries that perform viral load testing. Coded plasma samples of varying RNA levels, which
have been obtained from individual* HIV-1 infected and uninfected donors, are frozen
and mailed to approximately 200 MPEP participating laboratories. The laboratories are
asked to test the samples in the same manner they test routine or clinical specimens and
to provide MPEP with test results, test kit manufacturer information, test control/
calibrators/standards results, and quality-control practices. To assess intrashipment re-
producibility, selected samples in a panel are duplicated. To assess intershipment repro-
ducibility, all samples in each of two subsequent (i.e., replicate) shipments are identical,
except that the vial labeling and sequence are changed so that laboratories will not
receive samples containing the same coding or coding within an identical sequence as
the original survey. Before each survey, donor samples are characterized by reference
laboratories that use kits manufactured by Roche, Bayer, and Organon Teknika.
The distribution of laboratory types voluntarily participating in MPEP remained ap-
proximately the same during June 1997–February 2000 and included hospitals (52%),
independent laboratories (20.5%), health departments (17%), others (10%), and blood
banks (0.5%). Approximately 70% of the participating laboratories used the Roche kit in
all six survey periods; 22% used a Bayer kit; 6% used an Organon Teknika kit; and 2%
used an in-house–developed kit. Of the laboratories using the Roche Amplicor HIV-1
Monitor kit, approximately 25% indicated they had begun using the ultrasensitive proce-
dure. By the last two surveys, all laboratories using the Bayer kit were using the Bayer
HIV-1 RNA 3.0 Assay (bDNA); among the nine laboratories using an Organon Teknika kit,
all but one were using the NucliSens HIV-1 QT kit.
To provide information regarding the variability among laboratory test reporting,
results from within test kit manufacturers and within each survey during the six survey
periods were examined (Table 2). The median values determined from duplicate sample
testing results were reproducible, although variability occurred among the results re-
ported by laboratories using the same test kit and testing the same donor samples (i.e.,
the duplicate) within a survey or the same donor sample (i.e., the replicate) used in a later
survey. When the minimum and maximum values of the reported results were examined
for laboratories using the Roche Amplicor HIV-1 Monitor kit, the log difference ranged
from 0.8 to 2.2. Similarly, examination of the minimum and maximum reported values for
laboratories using the Organon Teknika NucliSens HIV-1 QT kit demonstrated a log differ-
ence range of 0.3–0.6. In comparison, a 0.5-log difference occurred within the minimum
and maximum reported results from laboratories using the Bayer HIV-1 RNA 3.0 Assay
(bDNA), which was the observed difference with all results reported for the same donor
sample within and among survey periods (Table 2). Among test kit manufacturers, the
*Samples are obtained from individual donors; samples from different donors are not pooled,
and individual samples are not diluted.
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median values determined from results reported by laboratories using the Roche
Amplicor HIV-1 Monitor and Organon Teknika NucliSens HIV-1 QT were consistently
higher than the median values determined from testing results reported by laboratories
using the Bayer HIV-1 RNA 3.0 Quantitative Assay (bDNA). This observation was true
only for the original sample in a survey and its duplicate. For the same sample used in a
later survey (i.e., the replicate), this observation was not true. Instead, good reproducibil-
ity* existed among the values reported for the replicate sample by laboratories using all
three manufacturers’ test kits. For these surveys, more laboratories use the Roche
Amplicor HIV-1 Monitor test kit than the other two kits. If the number of laboratories using
the other test kits matched the number of laboratories using the Roche Amplicor HIV-1
Monitor, the range in log difference for results reported by laboratories using the other
two test kits would probably increase.
Variation Among Laboratory Viral Load Test Reports
To understand laboratory practices regarding HIV viral load test reporting, a tele-
phone survey was conducted by San Diego State University (SDSU), under a coopera-
tive agreement with CDC, of randomly selected laboratories from three source groups:
medical schools, national commercial laboratories, and laboratories participating in CDC
MPEP. Laboratorians who are knowledgeable regarding HIV testing were interviewed,
and respondents were asked to fax or mail a copy of a negative and positive HIV RNA
report without patient identifiers.
A total of 212/279 (76%) telephone surveys were completed; of these, 112 (52.8%)
respondents performed HIV RNA testing. Of the respondents performing HIV RNA test-
ing, 3 (2.7%) were blood banks; 69 (61.6%) were hospitals; 11 (9.8%) were health depart-
ments; 24 (21.4%) were independent laboratories; and 5 (4.5%) were other laboratory types.
*Good reproducibility  can be defined as acceptable testing performance of duplicate and
replicate samples influencing the quality of precision and accuracy (Sources: Taylor JK.
Principles of quality assurance of chemical measurements. Gaithersburg, MD: US Department
of Commerce, National Bureau of Standards, 1985; publication no. NBSIR 85-3105; and
Taylor JK. Quality assurance of chemical measurements. Anal Chem 1981;53:1588A).
TABLE 2. Reported model performance evaluation participant laboratory results, by test
kit, for a human immunodeficiency virus-infected donor — June 1998 (original and duplicate
sample) and February 1999 (replicate sample)
Ribonucleic acid copies/mL
Number
Test kit Sample of Laboratories* Minimum Median Maximum Logdifference
†
Roche® Amplicor Original 69 72,821 169,419 489,627 0.8
HIV-1 Monitor™ Duplicate 69 77,066 169,843 1,291,635 2.2
Replicate 71 3,849 118,000 259,018 1.8
Bayer HIV-1 3.0 RNA Original 14 65,540 93,445 187,800 0.5
(branched deoxy- Duplicate 14 70,180 95,515 205,500 0.5
ribonucleic acid) Replicate 15 63,750 126,515 196,590 0.5
Organon Teknika Original 5 89,000 160,000 360,000 0.6
NucliSens® Duplicate 5 94,000 150,000 180,000 0.3
Replicate 5 110,000 125,500 200,000 0.3
* In certain cases, >1 samples were tested by one laboratory.
† Difference between minimum and maximum values for each test sample.
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Among the 112 respondents, 86 (76.8%) used the Roche Amplicor HIV-1 Monitor; 27
(24.1%) used the Bayer HIV-1 RNA 3.0 Quantitative Assay (bDNA); 11 (9.8%) used the
Organon Teknika NucliSens HIV-1 QT kit; and 6 (5.4%) used other methods (e.g., Digene™
and in-house–developed reagents). Multiple test kits were used by 15/112 (13.4%) re-
sponding laboratories. A total of 37 different laboratories, 9 (24.3%) independent, 7
(18.9%) health department, 19 (51.4%) hospital, and 2 (5.4%) other laboratories fur-
nished HIV RNA test reports. Of these 37 laboratories, all results were reported in copies/
mL; 5 (13.5%) reported in both copies/mL and log10 transformation.
Laboratories used different terminology to specify test limits, including the terms
linear range, reportable range, sensitivity level, detection levels or limits, and assay
limits. Using >1 terms, 26/37 (70.3%) laboratories specified the test kit’s lower limits; 12
(32.4%) reported upper limits; and 11 did not provide test limits. One laboratory that
specified both a lower limit and an upper limit when results were outside test kit limits did
not report the test limits when the results were within the test limit range. When the result
was outside the test limits, the report stated that the linear response range for the Roche
Amplicor HIV-1 Monitor Test was determined to be within 400–750,000 HIV-1 RNA
copies/mL, which is the linear range stated in the manufacturer’s insert (38 ). However,
when results were within test limits, the laboratory did not provide the statement indicat-
ing the manufacturer’s linear range, which indicated information inconsistency among
test reports.
In certain cases, laboratory slips indicated that HIV had been detected at a value
below the test’s lower limit (e.g., HIV detected was <400 copies/mL), or the laboratory slip
provided an actual number of copies outside of the stated reportable range. The test kit
used was reported on the test report form by 9/37 (24.3%) laboratories. Examples of
items appearing on the test reports that could introduce difficulty in interpreting test
results are provided in this report (Box).
• Assay detection limits not provided.
• Name of kit manufacturer not provided.
• Results difficult to locate.
• Incomplete units.
• Units separated from result.
• Exponential result requires conversion for test result interpretation.
• Result as written requires multiplication for final result.
• Expressed precision greater than precision designated for test kit.
• Small, difficult-to-read print.
• Footnote designator (e.g., an asterisk) without the footnote.
• Footnote without footnote designator (e.g., an asterisk).
• Including laboratory specimen preparation and assay number, which is unnecessary.
• Complex, lengthy, or extraneous laboratory comments.
• Multiple misspellings.
• Failure to comply with regulations by not indicating specimen collection date.
• Inadequate space allotted for results.
• Test results overlapping other data.
• Handwriting not interpretable.
• Including test optical density values, which is unnecessary.
• Including names of primers used, which is unnecessary.
• Report printing too faint or difficult to read.
• Including patient dilution factor, which is unnecessary.
*Examples excerpted from laboratory reports with personal identifiers deleted.
BOX. Items appearing on the human immunodeficiency virus type 1 viral load test
reports* that could cause difficulty in interpreting results
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RECOMMENDATIONS
The following recommendations were endorsed at the Human Retrovirus and Hepa-
titis C Laboratory Testing Conference (sponsored by APHL), held March 6–9, 2000, in
Charlotte, North Carolina. Good laboratory practice* requires that a discrete patient
identifier be provided to the laboratory with each specimen submitted for retrovirus
testing. Because laboratory reporting is critical to public health practice, information
regarding date of birth, sex, and racial/ethnic group should be included on the test report
form when available. Moreover, the laboratory report should be concise.
Required Items To Report
The following items must be included on the report form:
• Correct nomenclature for retroviruses.
• Name and address of the laboratory that performed the test.
• Date of specimen collection and receipt and report date.
• Identification of specimens having doubtful quality.
• Test kit name, manufacturer, and version.
• If required, correct wording regarding analyte specific reagents (ASR).
• Results obtained (laboratories must report test results according to the reportable
range specified in the manufacturer’s package insert and should not report values
outside that range).
— Results must be reported as a value in copies/mL and log10 transformation (e.g.,
500,000 copies/mL and log10 = 5.7).
— When the result is below the test’s lower detection limit, the result must be
reported as less than the lower limit of quantification for the test kit being used
(e.g., <400 copies/mL or <50 copies/mL).
— When the result is above the upper detection limit, the result must be reported
as greater than the upper limit of quantification for the test kit being used (e.g.,
>750,000 copies/mL or >500,000 copies/mL).
Optional Items To Report
The following items are optional for test report forms:
• Disclaimer stating that the test should not be used for unintended purposes.
• Changes from patient’s baseline and previous viral load values.
• Narrative explanations or results interpretation.
*Good laboratory practice  is defined as an acceptable way to perform a basic activity that is
known to influence the quality of its output (Source: Taylor JK. Good laboratory and good
measurement practices. In: Quality assurance of chemical measurements. Chelsea, MI: Lewis
Publishers, Inc., 1987;112–3.)
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• Reportable ranges, as specified in the manufacturer’s package insert.
• Statements regarding clinical consequences of recognizing variability among
assays.
Items Not To Be Included on Reports
The following items should not be included on the report form:
• Nonstandard abbreviations, clichés, and jargon.
• Statements regarding the sensitivity or specificity of results.
• Statements regarding confidentiality.
• Statements regarding AIDS.
• Statements regarding counseling.
• Information regarding primer, optical density, dilution factor, or preparation
method or assay number used.
• Prefinal results that require manipulations to obtain final results.
DISCUSSION
Although results from laboratories that use the three commercially produced assays
are strongly correlated, the absolute values of HIV viral load measured in the same
plasma sample by using two different assays can differ by >2-fold. Data from the MPEP
performance surveys demonstrate these differences and illustrate the need for contin-
ued surveillance of manufactured tests and laboratory performance. Until a common
standard is available to use for normalizing values obtained with different assay meth-
ods, choosing one assay method is advisable when HIV RNA levels are monitored to
guide therapeutic decision-making. The goal to develop a common standard for normal-
izing values obtained with different test kits has recently been reported (41 ). In that
study, 26 laboratories, representing 10 different countries, collaborated in establishing
the first international standard for HIV-1 RNA that can be used for nucleic acid-based
techniques. According to the SDSU survey of laboratory practices, <50% of the laborato-
ries indicated on the results slip what test had been used. Because this information is
used to interpret results, whether for clinical care or public health purposes, assay meth-
ods and test kit manufacturers should be noted on all viral load test reports.
SDSU’s survey indicated that all laboratories reported results in copies/mL, and cer-
tain laboratories also provided log10 transformation. Although changes can be monitored
by using either absolute or log10 values, absolute values are used to determine therapy
initiation. In addition, results expressed in both copies/mL and log10 might be useful to
health-care providers; therefore, reporting both is strongly recommended.
Available tests are not licensed for diagnosing HIV infection, but the viral load test
results are used for reporting HIV infection to local and state health departments (34 ).
Although future versions of these tests might be licensed for diagnostic purposes, health-
care providers should be aware that available viral load tests are only useful for monitor-
ing clinical status after an HIV diagnosis (35 ).
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Available test kits perform differently in detecting non-B subtypes (42–48 ). In the
United States, the Roche Amplicor HIV-1 Monitor version 1.0 is the most popular test for
determining viral load. However, it underdetects and underestimates non-B subtypes
(e.g., A, E, F, and G) when quantifying viral load (42–47 ). The Bayer HIV-1 RNA 3.0
Quantitative Assay (bDNA) probably quantifies RNA of different HIV-1 subtypes accu-
rately as a result of redundancy of multiple probes (43–45 ). The Organon Teknika
NucliSens HIV-1 QT assay also underdetects and underestimates divergent subtypes
(e.g., A and E) (43–45 ). All assays have problems amplifying HIV-1 group O and do not
amplify HIV-2. The Roche Monitor version 1.5 kit uses a new set of probes and primers
that reportedly detect and quantitate non-B subtypes with greater efficiency than the
previous version (42–46 ).
Plasma HIV RNA level provides a valid measure of antiretroviral therapy efficacy for
HIV-infected persons. Antiretroviral therapy suppression of HIV RNA level followed by
rebound levels might signal the emergence of drug-resistant HIV variants, suboptimal
adherence to the antiretroviral therapy regimen, decreased absorption of antiretroviral
drugs, altered drug metabolism because of physiologic changes, drug interactions, vac-
cinations, or concurrent infections. An HIV RNA level might be transiently elevated among
patients on therapy; the consequences of such elevations is unknown. HIV RNA levels
can vary by approximately threefold (0.5 log10) in either direction upon repeated mea-
surements among clinically stable, HIV-infected persons. Changes >0.5 log10 usually can-
not be explained by inherent biological or assay variability and likely reflect a biologically
and clinically relevant change in the level of plasma HIV RNA. However, plasma HIV RNA
assays vary greater toward the lower limits of sensitivity. Thus, differences between
repeated measures of >0.5 log10 might occur at low plasma HIV RNA values and might
not reflect a substantive biological or clinical change.
Viral load reporting has implications for clinical care and HIV/AIDS surveillance. State
public health programs are implementing recommendations by the Council of State and
Territorial Epidemiologists and CDC for nationwide HIV surveillance, including reporting
detectable RNA viral loads (34 ). As part of this reporting, laboratories and health-care
providers would be required to report HIV-infection cases to state and territorial health
departments. Standard methods are needed for viral load test reporting to providers and
health departments so that clinicians and public health professionals will have a common
language to use in conducting patient care and monitoring the epidemic.
To facilitate developing that common language, CDC and the Council of State and
Territorial Epidemiologists recommend that all states adopt rules or regulations to re-
quire reporting of detectable viral loads to public health departments. One state requires
reporting of undetectable viral load results based on the lower limit sensitivities of the
manufactured kits, but then follows up with health-care providers to document whether
the patient has other test results or clinical evidence indicative of infection with HIV.
Reporting of viral load test results by using standard nomenclature, test results presen-
tation, and electronic data transfer will permit reporting of HIV cases in a way that is
compatible with electronic laboratory efforts being developed for national notifiable
disease reporting (49 ).
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